BRAF and metastatic melanoma: Thus, due to the wide spectrum of antitumor capacities demonstrated by Ocoxin, we aimed to evaluate the antitumor potential of this compound in the progression of metastatic melanoma, its possible synergic effect with the BRAF inhibitor Vemurafenib, and its ability to modulate melanoma-CAF crosstalk driving to chemoresistance and disease progression in vitro and in vivo.